Myriad case is coming to US Supreme Court

The following is an excerpt.

For 30 years, companies have been patenting human genes. Yes, the very genetic material of our bodies, of our DNA, albeit in isolated forms. For longer than that, debates have been incessant — in the scientific community, between businesses, and in the courts — over whether or not this practice is legal, let alone ethical. Earlier this month, an Australian court heard yet another case about the legality of gene patenting, ultimately defending the practice. This spring, media attention over the controversy will shift back to the US as a similar case (originally heard in the US District Court for the Southern District of New York) will be heard by the Supreme Court.

View the original article here: The Case of Myriad Genetics: Should Companies Own Patents on Human Genes?


Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend